Pipeline Predictor Rx

Timothy Cummins

University of Massachusetts Medical School

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/commed_pubs

Part of the Health Services Administration Commons, Health Services Research Commons, and the Pharmacy and Pharmaceutical Sciences Commons

Repository Citation

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Commonwealth Medicine Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
The unbiased approach to predicting outcomes.™

Situation

It is well known that health care costs are continuously on the rise and with new prescription products entering the market almost weekly, it can be difficult to contain both pharmacy and medical costs and remain within a budget. Decision makers are faced with the challenge of evaluating these new products and determining their place in therapy. UMass Medical School’s Clinical Pharmacy Services (UMass) seeks out opportunities to engage decision makers within the realm of health insurance and managed care in conversation regarding the specific challenges they currently face and to identify their areas of need. Most recently, these discussions have highlighted an interest in finding ways to determine the potential budget impact, on both the pharmacy and medical side, for drugs that have recently entered or are about to enter the market.

Solution

In an effort to help meet this need, UMass has expanded into the field of economic modeling. By creating pharmacoeconomic comparisons, UMass is able to help decision makers proactively evaluate the potential impact of drugs that are in late stages of clinical development. These analytic models offer a comprehensive, customizable and unbiased supplement to the clinical information necessary to determine appropriate formulary placement. They provide information to support proactive formulary management of products that are expected to gain FDA approval as well as have a significant financial and clinical impact.

Results

One of the first models UMass created was a comparison of the investigational oral factor Xa inhibitor, rivaroxaban (Xarelto®), to enoxaparin. This model compares these agents for the prevention of venous thromboembolism after total hip replacement surgery. In order to gain feedback on the provision of this service, the model has been presented to various clinical experts within the University of Massachusetts clinical system as well as to our MassHealth and MedMetrics clients.

Benefits of Pipeline PredictorRx™

- Unbiased approach to pharmacoeconomic comparisons
- Academic medical center clinical expertise
- Customizable modeling utilizing client specific data
- Continual evaluation of models as new drug data becomes available
- Proactive formulary management tool

Contact:
Maria Ousterhout, PharmD
Clinical Consultant Pharmacist
Clinical Pharmacy Services
774-455-3201
Maria.Ousterhout@umassmed.edu
www.umassmed.edu/cps